Import from "@/components/mdx"

Mounjaro Regulatory Status: US, EU, Canada, and UK Approvals Explained

What Mounjaro Is and How It Works

Mounjaro is a once-weekly subcutaneous injection that activates two distinct hormone receptors simultaneously. No approved diabetes or weight drug before it did both. Understanding the mechanism explains why the regulatory story unfolded the way it did and why women with specific hormonal conditions may respond differently than the average clinical-trial participant.

Dual receptor agonism: GIP plus GLP-1

Tirzepatide binds to both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor FDA full prescribing information. GLP-1 receptor agonism is familiar territory: drugs like semaglutide and liraglutide work this pathway alone. GIP receptor agonism adds a separate insulin-secretion signal, reduces glucagon secretion, slows gastric emptying, and appears to enhance the central appetite-suppression effect of GLP-1.

The net result in SURPASS-2, a 40-week randomized trial published in the New England Journal of Medicine in 2021, was a mean A1C reduction of 2.01 percentage points with tirzepatide 15 mg versus 1.86 percentage points with semaglutide 1 mg, and a mean body-weight reduction of 12.4 kg versus 6.2 kg. Both figures favored tirzepatide at p < 0.001.

Why the mechanism matters specifically for women

Insulin resistance sits at the center of several female-specific conditions: polycystic ovary syndrome (PCOS), perimenopausal metabolic shift, and postpartum glucose dysregulation. GIP receptors are expressed in adipose tissue and the ovary. Whether ovarian GIP-receptor activation has meaningful reproductive effects in women has not been directly studied in clinical trials, and that evidence gap deserves candor. What is directly studied is the insulin-sensitizing and weight-reducing effect, both of which are clinically meaningful for women with PCOS or prediabetes entering perimenopause.

US Regulatory Status: FDA Approvals for Tirzepatide

The FDA has issued two separate approvals for tirzepatide under two separate brand names. This distinction matters practically because insurance coverage, prior-authorization criteria, and compounding restrictions differ between them.

Mounjaro: Type 2 diabetes (May 2022)

The FDA approved tirzepatide as Mounjaro on May 13, 2022, for adults with type 2 diabetes mellitus as an adjunct to diet and exercise FDA drug approval letter. Approved doses run from a 2.5 mg starting dose, titrated at four-week intervals to a maintenance dose of 5 mg, 10 mg, or 15 mg. The titration schedule exists specifically to reduce gastrointestinal side effects, which in SURPASS-2 affected 17 to 22 percent of tirzepatide participants (primarily nausea, diarrhea, and vomiting) compared with 18 percent on semaglutide.

Mounjaro carries a boxed warning for thyroid C-cell tumors based on rodent data. The human relevance is unknown, but it remains contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.

Zepbound: Chronic weight management (November 2023)

On November 8, 2023, the FDA approved tirzepatide under the brand name Zepbound specifically for chronic weight management in adults with a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity FDA Zepbound approval. The approval drew on SURMOUNT-1, a trial of 2,539 adults in which tirzepatide 15 mg produced a mean weight reduction of 22.5 percent from baseline over 72 weeks, compared with 2.4 percent on placebo.

Women made up approximately 67 percent of SURMOUNT-1 participants, which is a meaningful improvement over historical cardiovascular-outcomes trials but still leaves sex-stratified efficacy data in the supplementary tables rather than the headline results.

A practical framework for women navigating the two US brand names:

| Situation | Brand to discuss with prescriber | BMI threshold | |---|---|---| | Type 2 diabetes confirmed | Mounjaro | No BMI floor in label | | Obesity or overweight without diabetes | Zepbound | BMI 30, or BMI 27 with comorbidity | | PCOS with insulin resistance, no T2D diagnosis | Zepbound (off-label insulin resistance often cited) | BMI 27 if comorbidity documented | | Perimenopause with metabolic syndrome | Zepbound | BMI 27 with documented comorbidity |

EU Regulatory Status: EMA Approval

The European Medicines Agency (EMA) recommended marketing authorization for Mounjaro (tirzepatide) on September 22, 2022, with the European Commission issuing the formal decision shortly after EMA product page. The indication mirrors the US diabetes label: adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise, used as monotherapy or in combination with other glucose-lowering agents.

Dose and access differences in the EU

The EU label permits the same titration schedule as the US (2.5 mg to a maximum of 15 mg weekly). What differs is reimbursement: access under national health systems varies by member state. Germany, for example, listed tirzepatide for reimbursement through GKV-statutory insurance with some restrictions, while other EU countries are still completing health technology assessment processes. Women in countries with restricted reimbursement who need tirzepatide for diabetes may face out-of-pocket costs comparable to the US cash price.

Weight-management approval in the EU

As of early 2025, a separate weight-management indication for tirzepatide in the EU was under EMA review. The EMA had not yet issued a final decision on a Zepbound-equivalent approval for the EU at the time of publication. Women in the EU seeking tirzepatide for weight loss without a diabetes diagnosis should confirm the current status with their prescribing clinician, because the indication and reimbursement field is still moving.

Canada Regulatory Status: Health Canada Approval

Health Canada authorized Mounjaro for adults with type 2 diabetes in November 2022 Health Canada drug product database. The Canadian monograph follows a similar structure to the US and EU labels, with 2.5 mg initiation and titration to a maximum of 15 mg once weekly.

Canadian public drug plans (provincial formularies) vary widely in whether tirzepatide is listed. As of 2024, most provincial formularies had not added tirzepatide, meaning most Canadian women with type 2 diabetes pay out of pocket unless they have private insurance. A separate obesity indication for tirzepatide in Canada had not been approved as of early 2025. Women in Canada with PCOS, prediabetes, or obesity who are interested in tirzepatide for weight-related reasons should discuss both the off-label use question and the coverage question with their physician.

UK Regulatory Status: MHRA Approval

The Medicines and Healthcare products Regulatory Agency (MHRA) approved Mounjaro for adults with type 2 diabetes in November 2023 MHRA product information. The UK's approval came roughly a year after the EU, partly reflecting the post-Brexit regulatory pathway the MHRA now runs independently.

NHS access

The National Institute for Health and Care Excellence (NICE) issued guidance on tirzepatide for type 2 diabetes in 2023 NICE technology appraisal TA924, recommending it as an option for adults with type 2 diabetes when certain glycemic criteria are met and where other agents have not achieved adequate control. NHS prescription availability differs by integrated care board, and individual-funding requests remain a route for some patients whose local formulary has not yet listed the drug.

A weight-management indication for tirzepatide in the UK was in development with NICE appraisal expected to follow the MHRA's assessment, but had not been finalized as of early 2025.

Pregnancy, Lactation, and Contraception: A Required Safety Section for Women

Mounjaro (tirzepatide) is contraindicated in pregnancy. This is the most safety-critical point in the article for women of reproductive age, and it appears in the label of every jurisdiction covered above.

Why tirzepatide is contraindicated in pregnancy

Animal studies at doses producing exposures similar to human clinical doses showed fetal malformations, embryo-fetal death, and reduced fetal weight FDA full prescribing information. There are no adequate human data on tirzepatide use during pregnancy. Because animal reproductive toxicology studies signal risk, the precautionary position across all regulatory agencies is that tirzepatide should be stopped before a planned pregnancy.

The FDA label recommends discontinuing tirzepatide at least two months before a planned pregnancy because of the drug's long pharmacokinetic half-life of approximately five days FDA full prescribing information. In practical terms, two months is the minimum; many clinicians recommend stopping three to four months ahead of planned conception to give additional margin.

Lactation

Tirzepatide has not been studied in lactating women. It is unknown whether tirzepatide or its metabolites transfer into human breast milk. Given the animal toxicology signal and the absence of human lactation data, the current position across all four jurisdictions is that breastfeeding is not recommended during tirzepatide treatment. Women who are postpartum and breastfeeding should discuss the risk-benefit with their clinician before starting. This is a situation where the evidence gap is real and should be named clearly: we do not yet have human milk transfer studies for tirzepatide.

Contraception requirements

Women of reproductive age taking tirzepatide should use effective contraception. This is especially relevant for women with PCOS who have been told they are unlikely to conceive without assistance: weight loss from tirzepatide can restore ovulatory cycles, sometimes quickly and unexpectedly. A woman with PCOS who loses 10 to 15 percent of body weight may recover ovulation ASRM PCOS guideline before her periods have fully normalized, creating a conception risk she might not anticipate.

Oral contraceptive pills containing estrogen and progesterone may have slightly reduced absorption due to tirzepatide's effect on gastric emptying. The label advises using a backup or non-oral method of contraception for four weeks after starting tirzepatide and for four weeks after each dose escalation FDA full prescribing information. Long-acting reversible contraception (IUD, implant) sidesteps this interaction entirely.

Women-Specific Conditions and Life-Stage Considerations

Reproductive years and PCOS

PCOS affects approximately 6 to 12 percent of women of reproductive age in the US CDC PCOS data and is tightly linked to insulin resistance. Tirzepatide's dual mechanism directly targets insulin resistance, and the weight-loss magnitude seen in SURMOUNT-1 exceeds what metformin produces in most PCOS studies. No dedicated randomized trial of tirzepatide specifically in women with PCOS had been published as of early 2025. What is known comes from subgroup analyses and from extrapolating from the GLP-1-agonist PCOS literature, which showed menstrual regularization and androgen reduction with semaglutide and liraglutide. Whether tirzepatide's GIP component adds or subtracts from ovarian effects remains an open question.

Women with PCOS using tirzepatide off-label for insulin resistance or weight should be counseled explicitly on the contraception guidance above, because ovulatory recovery may precede any clinical signal.

Perimenopause and postmenopause

The perimenopausal transition shifts fat distribution from the hips toward visceral adiposity and worsens insulin resistance, independent of total weight Menopause journal, menopause and metabolic disease. Women entering perimenopause with prediabetes or metabolic syndrome may find that the glycemic drift that triggers a type 2 diabetes diagnosis accelerates during this transition.

Tirzepatide's approval does not differentiate by menopausal status, and the SURPASS and SURMOUNT trials did not report outcomes separately for peri- or postmenopausal women. The evidence gap here is meaningful. Clinicians prescribing tirzepatide to postmenopausal women with type 2 diabetes are extrapolating from a mixed trial population in which menopausal status was not a stratification variable.

One practical note: postmenopausal women do not face the oral-contraceptive interaction concern or the ovulatory-recovery risk described above, but they should still be informed that the pregnancy safety data is absent if they have any possibility of pregnancy.

Trying to conceive

If you are actively trying to conceive, tirzepatide should not be used. The two-month minimum washout period before conception attempts is a hard stop, not a suggestion. If weight loss before conception is a clinical goal, discuss a structured dietary intervention or whether metformin is more appropriate in the pre-conception window, given metformin's longer safety record in pregnancy.

Postpartum

Women who gained significant gestational weight and are not breastfeeding may ask about tirzepatide for postpartum weight management. No postpartum-specific trial exists. The practical minimum would be waiting until breastfeeding is fully stopped, then waiting an additional period for hormonal stabilization, typically at least six weeks postpartum, before initiating. Any use in this context is off-label and should be discussed with a clinician who knows your full postpartum picture.

Who Mounjaro Is and Is Not Right For (by Life Stage and Condition)

May be appropriate

• Adult women with type 2 diabetes who have not reached A1C goal on metformin or other first-line agents (all four jurisdictions, on-label)
• Adult women with obesity (BMI 30 or higher) or overweight with a comorbidity (BMI 27 or higher) in the US, using Zepbound (on-label)
• Women with PCOS, insulin resistance, and obesity who have not responded to first-line lifestyle and metformin (off-label in most jurisdictions, evidence extrapolated)
• Perimenopausal women with new-onset type 2 diabetes or obesity-related comorbidities (on-label by indication, evidence extrapolated by life stage)

Not appropriate

• Women who are pregnant or planning pregnancy within two months (contraindicated)
• Women who are breastfeeding (not recommended, no human lactation data)
• Women or people with a personal or family history of medullary thyroid carcinoma or MEN2 (contraindicated in all jurisdictions)
• Women with a history of pancreatitis (caution; discuss risk-benefit with clinician)
• Women in the EU, Canada, or UK who want tirzepatide for weight loss without a diabetes diagnosis and where a weight-management indication has not yet been approved (access depends on off-label prescribing practices locally)

Regulatory Comparison at a Glance

| Jurisdiction | Regulatory Body | Diabetes Approval | Weight-Loss Approval | Brand Name(s) | |---|---|---|---|---| | United States | FDA | May 2022 | November 2023 | Mounjaro (T2D), Zepbound (weight) | | European Union | EMA | September 2022 | Under review (as of early 2025) | Mounjaro | | Canada | Health Canada | November 2022 | Not approved (as of early 2025) | Mounjaro | | United Kingdom | MHRA | November 2023 | Under review (as of early 2025) | Mounjaro |

How the Evidence Base Has Developed (and Where the Gaps Remain)

The SURPASS program covered six major trials across different comparators and patient populations. SURPASS-2 compared tirzepatide head-to-head against semaglutide 1 mg in 1,879 adults with type 2 diabetes and demonstrated superiority on both A1C reduction and body weight at 40 weeks. The SURPASS-CVOT cardiovascular-outcomes trial (SURPASS-CVOT, published in the New England Journal of Medicine in 2024) showed a 17 percent relative risk reduction in major adverse cardiovascular events with tirzepatide compared with dulaglutide in adults with type 2 diabetes and established cardiovascular disease or high cardiovascular risk NEJM SURPASS-CVOT.

Women represented roughly 30 percent of SURPASS-CVOT participants. That figure is low for a drug that women with PCOS, metabolic syndrome, and perimenopausal insulin resistance may be taking for years. The cardiovascular-risk reduction data for tirzepatide in women is therefore drawn from a minority subgroup, not a sex-balanced trial. The Menopause Society's 2023 position statement on menopause and cardiovascular risk menopause.org highlights that postmenopausal women carry specific cardiovascular risk profiles that clinical trials often do not fully capture.

Bone health is another area where female-specific data on tirzepatide is thin. Rapid weight loss accelerates bone resorption, an effect documented with bariatric surgery and observed in GLP-1 agonist trials. Women in perimenopause or postmenopause who are already losing bone density should discuss this with their clinician before starting tirzepatide, even though the current label does not contain a specific bone-loss warning.

What to Ask Your Prescriber Before Starting

Before your first prescription is written, these questions will help you get a complete picture:

• Which brand name and indication are you prescribing, and is this on-label for my jurisdiction?
• Given my contraceptive method, do I need a backup method for the first four weeks and after each dose increase?
• If I have PCOS and my cycles are irregular, how will we monitor for ovulatory recovery?
• If I am perimenopausal, what bone-density baseline should we establish before starting?
• What is the stopping plan if I want to become pregnant in the next year?

Women with type 2 diabetes taking tirzepatide at 15 mg weekly can expect, based on SURPASS-2 data, a mean A1C reduction of approximately 2.0 percentage points and a mean weight loss of roughly 12 kg over 40 weeks, SURPASS-2, NEJM 2021. Those numbers come from a mixed-sex trial population; your individual result will depend on baseline A1C, adherence, diet, and hormonal status at the time you start.